Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Ko

Cardiovascular Disease Sacramento, CA Medical Doctor

NPI 1972605541 CMS profile 180103

6600 Bruceville Rd, Sacramento, CA 95823

Open in the dashboard

General payments

$10,503

329 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Ko of Sacramento, CA is reported in the CMS Open Payments database as having received $10,503 across 329 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,022 43
2024 General $1,296 33
2023 General $1,596 57
2022 General $1,978 93
2021 General $1,837 76
2020 General $343 19
2019 General $432 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Ko
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to John Ko were reported at $3,022. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year John Ko Cardiovascular Disease median Middle half National median
2019 $432 $450 $127–$1,392 $163
2020 $343 $242 $77–$751 $114
2021 $1,837 $335 $101–$1,037 $132
2022 $1,978 $395 $121–$1,211 $149
2023 $1,596 $443 $136–$1,283 $160
2024 $1,296 $450 $136–$1,323 $164
2025 $3,022 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $3,815 111 payments
  2. Boston Scientific Corporation $3,153 167 payments
  3. Abbott Laboratories $2,305 32 payments
  4. Shockwave Medical, Inc $450 7 payments
  5. Abiomed $289 4 payments
  6. Chiesi USA, Inc. $147 2 payments
  7. Teleflex LLC $136 1 payment
  8. Medtronic Vascular, Inc. $106 2 payments
  9. Edwards Lifesciences Corporation $84 2 payments
  10. Terumo Medical Corporation $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,218 322 payments
  2. Travel and Lodging $1,218 6 payments
  3. Grant $66 1 payment
Products named General payments · program years 2019–2025
  1. TRICLIP $1,377 8 payments
  2. FFRANGIO $676 16 payments
  3. Telescope $675 28 payments
  4. ONYX FRONTIER $671 17 payments
  5. SYNERGY Stents $554 30 payments
  6. COREVALVE EVOLUT R $488 6 payments
  7. SYNERGY Synergy_Ic $465 32 payments
  8. DxTerity $371 18 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $368 3 payments
  10. CoreValve Evolut $290 3 payments
  11. Other $4,302 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

283

Median for Cardiology: 2,533

Drug cost

$39,100

Median for Cardiology: $485,213

Branded share of claims

30.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 12 $17,633
Eliquis Apixaban Brand 12 $11,338
Jardiance Empagliflozin Brand 13 $6,709
Atorvastatin Calcium Generic 57 $751
Clopidogrel Clopidogrel Bisulfate Brand 28 $546
Furosemide Generic 32 $395
Metoprolol Succinate Generic 34 $395
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 11 $353
Metoprolol Tartrate Generic 24 $278
Lisinopril Generic 19 $195

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$5,733

Medicare's payments for the services billed

Medicare patients

16

Average age 71

Services billed

37

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

329 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record